vs
Side-by-side financial comparison of Service Properties Trust (SVC) and Bio-Techne (TECH). Click either name above to swap in a different company.
Service Properties Trust is the larger business by last-quarter revenue ($296.5M vs $295.9M, roughly 1.0× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -0.3%, a 13.1% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-6.4% vs -17.0%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -6.1%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
SVC vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $296.5M | $295.9M |
| Net Profit | $-782.0K | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -3.9% | 18.4% |
| Net Margin | -0.3% | 12.8% |
| Revenue YoY | -17.0% | -6.4% |
| Net Profit YoY | 99.0% | 68.3% |
| EPS (diluted) | $-0.01 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $296.5M | $295.9M | ||
| Q3 25 | $377.6M | — | ||
| Q2 25 | $404.4M | $317.0M | ||
| Q1 25 | $335.0M | $316.2M | ||
| Q4 24 | $357.0M | $297.0M | ||
| Q3 24 | $390.9M | $289.5M | ||
| Q2 24 | $412.5M | $306.1M | ||
| Q1 24 | $336.2M | $303.4M |
| Q4 25 | $-782.0K | $38.0M | ||
| Q3 25 | $-46.9M | — | ||
| Q2 25 | $-38.2M | $-17.7M | ||
| Q1 25 | $-116.4M | $22.6M | ||
| Q4 24 | $-76.4M | $34.9M | ||
| Q3 24 | $-46.9M | $33.6M | ||
| Q2 24 | $-73.8M | $40.6M | ||
| Q1 24 | $-78.4M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | -3.9% | 18.4% | ||
| Q3 25 | -12.8% | — | ||
| Q2 25 | -9.2% | -7.5% | ||
| Q1 25 | -33.3% | 12.2% | ||
| Q4 24 | -19.4% | 16.0% | ||
| Q3 24 | -12.8% | 13.8% | ||
| Q2 24 | -17.1% | 15.0% | ||
| Q1 24 | -21.4% | 22.1% |
| Q4 25 | -0.3% | 12.8% | ||
| Q3 25 | -12.4% | — | ||
| Q2 25 | -9.4% | -5.6% | ||
| Q1 25 | -34.8% | 7.1% | ||
| Q4 24 | -21.4% | 11.7% | ||
| Q3 24 | -12.0% | 11.6% | ||
| Q2 24 | -17.9% | 13.3% | ||
| Q1 24 | -23.3% | 16.2% |
| Q4 25 | $-0.01 | $0.24 | ||
| Q3 25 | $-0.28 | — | ||
| Q2 25 | $-0.23 | $-0.11 | ||
| Q1 25 | $-0.70 | $0.14 | ||
| Q4 24 | $-0.46 | $0.22 | ||
| Q3 24 | $-0.28 | $0.21 | ||
| Q2 24 | $-0.45 | $0.26 | ||
| Q1 24 | $-0.48 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $346.8M | $172.9M |
| Total DebtLower is stronger | $5.5B | $260.0M |
| Stockholders' EquityBook value | $646.1M | $2.0B |
| Total Assets | $6.5B | $2.5B |
| Debt / EquityLower = less leverage | 8.52× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $346.8M | $172.9M | ||
| Q3 25 | $417.4M | — | ||
| Q2 25 | $63.2M | $162.2M | ||
| Q1 25 | $80.1M | $140.7M | ||
| Q4 24 | $143.5M | $177.5M | ||
| Q3 24 | $48.6M | $187.5M | ||
| Q2 24 | $14.6M | $152.9M | ||
| Q1 24 | $71.3M | $145.3M |
| Q4 25 | $5.5B | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $5.8B | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $646.1M | $2.0B | ||
| Q3 25 | $647.9M | — | ||
| Q2 25 | $695.9M | $1.9B | ||
| Q1 25 | $734.6M | $2.0B | ||
| Q4 24 | $851.9M | $2.1B | ||
| Q3 24 | $929.0M | $2.1B | ||
| Q2 24 | $1.0B | $2.1B | ||
| Q1 24 | $1.1B | $2.0B |
| Q4 25 | $6.5B | $2.5B | ||
| Q3 25 | $7.0B | — | ||
| Q2 25 | $6.9B | $2.6B | ||
| Q1 25 | $7.0B | $2.6B | ||
| Q4 24 | $7.1B | $2.7B | ||
| Q3 24 | $7.1B | $2.7B | ||
| Q2 24 | $7.1B | $2.7B | ||
| Q1 24 | $7.2B | $2.7B |
| Q4 25 | 8.52× | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 6.85× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.5M | — |
| Free Cash FlowOCF − Capex | $-95.2M | — |
| FCF MarginFCF / Revenue | -32.1% | — |
| Capex IntensityCapex / Revenue | 25.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-107.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.5M | — | ||
| Q3 25 | $98.1M | — | ||
| Q2 25 | $-7.0K | $98.2M | ||
| Q1 25 | $38.2M | $41.1M | ||
| Q4 24 | $-9.7M | $84.3M | ||
| Q3 24 | $106.2M | $63.9M | ||
| Q2 24 | $43.8M | $75.5M | ||
| Q1 24 | $-926.0K | $81.0M |
| Q4 25 | $-95.2M | — | ||
| Q3 25 | $57.9M | — | ||
| Q2 25 | $-46.6M | $93.3M | ||
| Q1 25 | $-23.2M | $31.0M | ||
| Q4 24 | $-88.9M | $77.5M | ||
| Q3 24 | $24.1M | $54.7M | ||
| Q2 24 | $-22.3M | $57.5M | ||
| Q1 24 | $-77.2M | $64.5M |
| Q4 25 | -32.1% | — | ||
| Q3 25 | 15.3% | — | ||
| Q2 25 | -11.5% | 29.4% | ||
| Q1 25 | -6.9% | 9.8% | ||
| Q4 24 | -24.9% | 26.1% | ||
| Q3 24 | 6.2% | 18.9% | ||
| Q2 24 | -5.4% | 18.8% | ||
| Q1 24 | -23.0% | 21.3% |
| Q4 25 | 25.9% | — | ||
| Q3 25 | 10.6% | — | ||
| Q2 25 | 11.5% | 1.5% | ||
| Q1 25 | 18.3% | 3.2% | ||
| Q4 24 | 22.2% | 2.3% | ||
| Q3 24 | 21.0% | 3.2% | ||
| Q2 24 | 16.0% | 5.9% | ||
| Q1 24 | 22.7% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SVC
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
